Zacks Research Has Positive Forecast for ResMed Q2 Earnings

ResMed Inc. (NYSE:RMD) – Investment analysts at Zacks Research increased their Q2 2026 earnings estimates for shares of ResMed in a note issued to investors on Thursday, January 8th. Zacks Research analyst Team now expects that the medical equipment provider will post earnings per share of $2.66 for the quarter, up from their previous forecast of $2.63. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q3 2026 earnings at $2.69 EPS, Q4 2026 earnings at $2.71 EPS, FY2026 earnings at $10.62 EPS, Q1 2027 earnings at $2.63 EPS, Q2 2027 earnings at $2.73 EPS, Q3 2027 earnings at $2.83 EPS, Q4 2027 earnings at $3.01 EPS, FY2027 earnings at $11.20 EPS, Q1 2028 earnings at $3.11 EPS, Q2 2028 earnings at $3.14 EPS and FY2028 earnings at $12.80 EPS.

Several other research analysts also recently weighed in on the company. Robert W. Baird restated a “neutral” rating and issued a $275.00 price target (down from $300.00) on shares of ResMed in a research note on Tuesday, December 16th. Wells Fargo & Company assumed coverage on shares of ResMed in a report on Monday, October 13th. They issued an “equal weight” rating and a $280.00 target price on the stock. KeyCorp raised their target price on shares of ResMed from $298.00 to $299.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. UBS Group reiterated a “buy” rating and issued a $345.00 price target on shares of ResMed in a report on Friday, December 12th. Finally, Morgan Stanley set a $305.00 price objective on shares of ResMed in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $296.09.

ResMed Stock Performance

NYSE:RMD opened at $257.75 on Monday. The stock has a 50-day moving average price of $248.63 and a 200 day moving average price of $263.26. The stock has a market capitalization of $37.62 billion, a P/E ratio of 26.38, a P/E/G ratio of 1.70 and a beta of 0.88. ResMed has a 12-month low of $199.92 and a 12-month high of $293.81. The company has a current ratio of 2.89, a quick ratio of 2.13 and a debt-to-equity ratio of 0.07.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Friday, October 31st. The medical equipment provider reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. ResMed had a return on equity of 25.45% and a net margin of 27.35%.The business had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same period last year, the firm earned $2.20 earnings per share. The business’s quarterly revenue was up 9.1% on a year-over-year basis.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Thursday, November 13th were issued a $0.60 dividend. The ex-dividend date of this dividend was Thursday, November 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. ResMed’s dividend payout ratio (DPR) is presently 24.56%.

Insider Buying and Selling

In other news, Director Witte Jan De sold 2,055 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total transaction of $524,025.00. Following the transaction, the director owned 4,261 shares of the company’s stock, valued at approximately $1,086,555. The trade was a 32.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael J. Farrell sold 8,011 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $249.75, for a total value of $2,000,747.25. Following the sale, the chief executive officer owned 467,866 shares in the company, valued at $116,849,533.50. The trade was a 1.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 21,594 shares of company stock worth $5,403,495. Corporate insiders own 0.65% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RMD. Norges Bank purchased a new position in shares of ResMed during the 2nd quarter worth about $306,452,000. First Trust Advisors LP lifted its stake in ResMed by 285.1% in the third quarter. First Trust Advisors LP now owns 445,198 shares of the medical equipment provider’s stock worth $121,864,000 after purchasing an additional 329,588 shares during the last quarter. Marshall Wace LLP boosted its position in shares of ResMed by 2,373.1% during the third quarter. Marshall Wace LLP now owns 310,987 shares of the medical equipment provider’s stock valued at $85,126,000 after buying an additional 298,412 shares during the period. Nordea Investment Management AB grew its stake in shares of ResMed by 37.2% during the fourth quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock valued at $262,027,000 after buying an additional 294,124 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of ResMed by 1.6% during the third quarter. Vanguard Group Inc. now owns 19,040,440 shares of the medical equipment provider’s stock valued at $5,211,940,000 after buying an additional 293,515 shares during the last quarter. Institutional investors own 54.98% of the company’s stock.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.